| Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma N Scholler, R Perbost, FL Locke, MD Jain, S Turcan, C Danan, EC Chang, ... Nature medicine 28 (9), 1872-1882, 2022 | 100 | 2022 |
| Resistance of hepatitis C virus to NS3–4A protease inhibitors: Mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations J Courcambeck, M Bouzidi, R Perbost, B Jouirou, N Amrani, P Cacoub, ... Antiviral Therapy 11 (7), 847-856, 2006 | 68 | 2006 |
| Influence of cation size on the curvature of serpentine minerals: HRTEM-AEM study and elastic theory R Perbost, M Amouric, J Olives Clays and clay minerals 51, 430-438, 2003 | 28 | 2003 |
| Pyrrolidine derivatives for use in treating heaptitis c virus infection P Halfon, C Sayada, JM Feryn, R Perbost, F Garzino, M Camplo, ... US Patent App. 10/534,905, 2006 | 22 | 2006 |
| Mixed layering of illite-smectite: Results from high-resolution transmission electron microscopy and lattice-energy calculations J Olives, M Amouric, R Perbost Clays and Clay Minerals 48 (2), 282-289, 2000 | 21 | 2000 |
| Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma FL Locke, S Filosto, J Chou, S Vardhanabhuti, R Perbost, P Dreger, ... Nature Medicine 30 (2), 507-518, 2024 | 17 | 2024 |
| Prediction of molecular crystal structures using a genetic algorithm: Validation by GenMol™ on energetic compounds G Pepe, R Perbost, J Courcambeck, P Jouanna Journal of crystal growth 311 (13), 3498-3510, 2009 | 12 | 2009 |
| Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in … FL Locke, J Chou, S Vardhanabhuti, R Perbost, P Dreger, BT Hill, C Lee, ... Journal of Clinical Oncology 40 (16_suppl), 7565-7565, 2022 | 7 | 2022 |
| Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma … JM Rossi, J Galon, E Chang, R Perbost, N Scholler, S Turcan, C Danan, ... Cancer research (Chicago, Ill.) 79 (13_Supplement), CT153-CT153, 2019 | 7 | 2019 |
| Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel … J Galon, N Scholler, R Perbost, S Turcan, C Danan, FL Locke, ... Journal of Clinical Oncology 38 (15_suppl), 3022-3022, 2020 | 5 | 2020 |
| Prediction of HIV-1 protease inhibitor resistance by Molecular Modeling Protocols (MMPs) using GenMol™ software G Pepe, J Courcambeck, R Perbost, P Jouanna, P Halfon European journal of medicinal chemistry 43 (11), 2518-2534, 2008 | 5 | 2008 |
| Entry inhibitor GNS 037 exhibits potent anti-HCV activity in vitro P Halfon, JM Sabatier, R Perbost, B Jouirou, P Cacoub, D Lavilette, ... Hepatology 42 (4), 236A-236A, 2005 | 3 | 2005 |
| Pyrrolidine derivatives for use in treating heaptitis c virus infection P Halfon, C Sayada, JM Feryn, R Perbost, F Garzino, M Camplo, ... | 1 | 2004 |
| Structure et stabilité de phyllosilicates interstratifiés. Expérimentation et modélisations R Perbost Aix-Marseille 3, 2001 | 1 | 2001 |
| Abstract LB346: Dynamic changes in the tumor microenvironment from initial diagnosis through sequential therapies in patients with large B cell lymphoma undergoing axicabtagene … M Mattie, R Perbost, A Auguste, S Turcan, JJ Kim, C To, J Nater, S Filosto, ... Cancer Research 84 (7_Supplement), LB346-LB346, 2024 | | 2024 |
| Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma MD Mattie, R Perbost, S Turcan, C Danan, FL Locke, SS Neelapu, ... Cancer Research 83 (7_Supplement), 5879-5879, 2023 | | 2023 |
| 1454 Multiomics and multimodal analysis approach to construct a diffuse large B cell lymphoma atlas of tumor microenvironment for predictive modeling M Mattie, R Perbost, S Turcan, C Danan, F Locke, S Neelapu, D Miklos, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED … FL Locke, J Chou, S Vardhanabhuti, R Perbost, P Dreger, BT Hill, C Lee, ... HemaSphere 6, 1084-1085, 2022 | | 2022 |
| Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture T Sbarrato, L Vanhille, M Filahi, C Davin, A Martirosyan, V Fraysinnet, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| Nano structures and thermodynamic properties of clay minerals: illite, smectite and mixed-layer illite-smectite H Gailhanou, J Olives, M Amouric, R Perbost, J Rogez, JC Van Miltenburg, ... | | 2005 |
